Jazz Pharmaceuticals (JAZZ) Total Debt (2010 - 2026)

Jazz Pharmaceuticals' Total Debt history runs 17 years deep, the most recent figure standing at $5.4 billion for Q1 2026.

• On a quarterly basis, Total Debt fell 0.81% year-over-year to $5.4 billion in Q1 2026; TTM through Mar 2026 was $5.4 billion, a 0.81% decrease from a year earlier, with the FY2025 full-year figure at $6.4 billion, up 4.58% from the prior year.
• Total Debt eased to $5.4 billion in Q1 2026 per JAZZ's latest filing, from $6.4 billion in the prior quarter.
• Across five years, Total Debt topped out at $6.4 billion in Q2 2025 and bottomed at $5.4 billion in Q1 2026.
• The 5-year median for Total Debt is $5.8 billion (2022), against an average of $5.9 billion.
• Biggest YoY gain for Total Debt was 186.63% in 2022; the steepest drop was 13.38% in 2022.
• Year by year, Total Debt stood at $5.7 billion in 2022, then declined by 0.2% to $5.7 billion in 2023, then advanced by 6.93% to $6.1 billion in 2024, then increased by 4.58% to $6.4 billion in 2025, then fell by 16.18% to $5.4 billion in 2026.
• Per Business Quant, the three latest JAZZ Total Debt figures stand at $5.4 billion (Q1 2026), $6.4 billion (Q4 2025), and $6.4 billion (Q3 2025).